Eptinezumab

Drug Profile

Eptinezumab

Alternative Names: ALD-403

Latest Information Update: 12 Jul 2017

Price : $50

At a glance

  • Originator Alder Biopharmaceuticals
  • Class Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Migraine

Most Recent Events

  • 27 Jun 2017 Efficacy data from the phase III PROMISE 1 trial in Migraine released by Alder BioPharmaceuticals
  • 28 Apr 2017 Efficacy and adverse events data from a phase II trial in Migraine (Prevention) reported at the 69th annual meeting of the American Academy of Neurology (AAN-2017)
  • 28 Apr 2017 Positive top-line results from a phase II trial in Migraine reported at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top